Action

FGFRs

Alt Name

Approval Jurisdiction

2019 FDA

Approved for clinical use

Advanced metastatic urothelial carcinoma

Brutto

CAS

1346242-81-6

Commercial Vendor

Janssen

Compound Image

Erdafitinib.png

Compound name

Erdafitinib

InChI

InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3

InChI Key

OLAHOMJCDNXHFI-UHFFFAOYSA-N

MW

446.50

PubChem CID

67462786

Reference

Reference 2

SMILES

CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC

Approved Drug List

1